Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The Arrhythmia At 12 Months Post Ablation
Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.
As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:
100% accurate identification of the site of origin to the exact or neighboring cardiac segment
17 (≈95%) patients had successful ablation procedures
83% of patients had no recurrence of the arrhythmia at 12 months post ablation
